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ABSTRACT
Background: Empiric therapy of severe group B streptococcal (GBS) infections, started before 
availability of susceptibility results, and intrapartum chemoprophylaxis to prevent early neonatal GBS 
disease are based on accurate susceptibility surveillance data. Increase of erythromycin (E) and 
clindamycin (C) resistance (R) is observed in GBS isolates in many countries.  In Belgium, E-R 
increased up to 10 % through the 1990s and reached 19% overall with 30 % among adult isolates in 
2001-2002.
Methods: 178 GBS clinical isolates from invasive GBS diseases consecutively received by the 
reference laboratory between January 2005 and June 2006, were from 32 neonates (22 early-onset 
and 10 late-onset diseases) and 146 adults.  Penicillin (P), E and C MICs were determined by using 
Etest® strips (CLSI interpretive criteria).  Furthermore, for the E-R isolates, the inducible (iMLS), 
constitutive (cMLS) and M phenotypes were assessed by a double-disk diffusion test and the 
distribution of genes encoding RNA methylases and efflux pumps was investigated by PCR. 
Results: All strains were susceptible (S) to P, 32% of isolates were R to E, with a higher rate of R 
among serotype V (57%, p <0,001) and 19% were R to C.
Among the 58 E-R isolates, 79% exhibited the MLSB phenotype (R to E and C), 26 were cMLS with 
E MIC50 >256 mg/L and 20 iMLS with E MIC50/MIC90 4/>256 mg/L.  The M phenotype (R to E and S 
to C) was expressed by 12 (21%) of E-R isolates with E MIC50/MIC90 4/12 mg/L
The most common E-R genotypes were ermTR (36%) and ermB (34%), followed by mefA (14%), 
ermB+ermTR (12%) and ermTR+mefA (2%). 
Conclusions: 1) P remains active against all isolates.  2) Prevalence of macrolides R has increased 
since the 1990s and is particularly high among serotype V isolates. 3) E-R is mainly caused by 
target-site modification (ermB, ermTR) mechanisms; efflux (mefA) R mechanism is also prevalent 
among these isolates. 4) R surveillance is mandatory to guide prophylaxis and treatment of serious 
GBS infections.
BACKGROUND
Group B streptococcus (GBS) or Streptococcus agalactiae is the leading cause of 
meningitis and sepsis in neonates and also a serious cause of mortality or morbidity  in 
adults with underlying diseases.  Penicillin is the first line antibiotic for the treatment of 
GBS infections or for intrapartum chemoprophylaxis, but erythromycin and clindamycin
are effective recommended alternatives in the penicillin allergic patients. Empiric 
therapy of severe group B streptococcal (GBS) infections, starting before availability of 
susceptibility results, and intrapartum chemoprophylaxis to prevent early neonatal GBS 
disease are based on accurate susceptibility surveillance data.
Probably as a consequence of an important use of erythromycin, macrolides and 
related drugs, resistance among streptococcal isolates has been increasing in many 
countries. Through the 1990s, among clinically significant isolates of S.agalactiae
collected in different areas of Belgium, erythromycin resistance increased from 3 to 
10%. In 1999, erythromycin resistance among invasive and colonizing GBS isolates, 
fluctuated between 10 and 20 %. In 2001-2002, it reached 19% overall with 30 % 
among isolates from adults with invasive infection.
Different known mechanisms account for acquired resistance to macrolides in 
streptococci as the target site modification by 23S rRNA methylases, encoded by erm
genes.  The Erm enzymes confer cross-resistance to macrolides, lincosamides and the 
streptogramin B compounds, so-called MLSB phenotype. MLS-resistance may be 
inducible or constitutive. Another mechanism involving an active efflux, only affects 14-
and 15-membered macrolides but not 16-membered macrolides, neither lincosamides
or streptogramins (M phenotype) and is encoded by mef genes.
OBJECTIVES
 To monitor penicillin susceptibility among GBS recently isolated in 
Belgium from either neonates or adults with severe infections. 
 To determine the rate of erythromycin (ERY) and clindamycin (CLI) 
resistance (R) among the same invasive isolates. 
 To assess the distribution of macrolide resistance phenotypes and 
to identify the resistance genes, ermB, ermTR and mefA, among the 
erythromycin-resistant isolates. 
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METHODS
Clinical isolates
Any Belgian laboratory is invited to send to the National Reference Laboratory (NRL) 
for GBS all their S.agalactiae isolated from severe infection (from blood, CSF or any 
deep normally sterile site) for further characterization and epidemiological purposes. 
A total of 178 clinical GBS strains isolated between January 2005 and June 2006  
were included in this study: 22 isolates from early-onset neonatal disease, 10 from 
late-onset neonatal disease and 146 from adult invasive infections.  
Serotypes were distributed as it follows: 17% Ia, 6% Ib, 10% II, 33% III, 6% IV, 21% V 
and 7% others (VI, VII and non typable).
All strains were stored in skimmed milk at  -80°C.
Reference strains for specific genes, 
GBS previously characterized, belonging to the collection of the NRL for GBS: 
• Two strains for ermB gene (Ref.1546 and 1628), one for ermTR gene (Ref. 97123) 
and one for mefA gene (ref.167).
• Five strains as negative control (Ref. 1732, 1734, 1741, 1745 and 1747)
Determination of susceptibility and MICs
 Disks diffusion : erythromycin (15 µg) and clindamycin (2 µg) (Becton Dickinson, USA) 
for all isolates
 Etest® method (AB Biodisk, Sweden): benzylpenicilline strips for all isolates, 
erythromycin & clindamycin strips for all isolates identified ERY-R by the disk 
diffusion test
 Inoculum 0.5 McFarland on Mueller-Hinton agar + 5% sheep blood
 Incubation 18-24h at 35°C
 MIC breakpoints and interpretive standards (CLSI January 2006)
Determination of macrolide resistance phenotypes
 Erythromycin (15 µg) and clindamycin (2 µg) double-disk diffusion assay
 Disks placed 18 mm apart (edge to edge) on inoculated Mueller Hinton agar + 5% 
sheep blood ; 18-24 h incubation at 35°C. 
 MLSB phenotypes:
• Inducible resistance (IR): blunting of the clindamycin zone of inhibition 
proximal to the erythromycin disk or “D shaped zone”
•Constitutive resistance (CR): resistance to both erythromycin and 
clindamycin
 M phenotype: susceptibility to clindamycin with no blunting of the clindamycin zone 
of inhibition.
Detection of resistance genes 
 DNA extraction using QIAmp DNA Mini Kit (Qiagen)
 PCR amplifications with specific primers enabling detection of target genes
Protocol of PCR using gene specific primers for known macrolide resistance markers
Thermocycler : PxE1,2 (Hybaid, Canada) 
Following amplification and further separation by electrophoresis on 2% agarose gel 










erm B   30 94°C - 60 s 54°C - 60 s 640
erm TR 35 94°C - 30 s 45°C - 90 s 530
mef A 30 94°C - 60 s 52°C - 60 s 348
94°C - 10 
min 
72°C - 1 
min
72°C - 5 
min
RESULTS
 Antimicrobial susceptibility profile
Antimicrobial susceptibility profile of 178 clinical isolates of GBS 
(January 2005 - June 2006)
 Erythromycin Resistance & evolution
GBS Resistance to erythromycin among different groups of patients
and per serotype (January 2001-March 2003 and January 2005-June 2006)
Within the first period, isolates from adults and serotype V isolates were 
significantly more resistant to erythromycin (p<0.01 and p< 0.001).
More recently, neonatal isolates have demonstrated the same level of resistance 
to erythromycin as adult isolates.  And, serotypes IV, V, VI and VII are more 


































 Macrolide resistance phenotypes
Distribution of macrolide resistance phenotypes  among  58 isolates 
of GBS resistant to erythromycin
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 Distribution of macrolide resistance genes within  
the different phenotypes
Distribution of the ermTR, ermB and mefA genes within the different 




































 As in the different surveillance studies of GBS antimicrobial susceptibilities, all isolates remain fully susceptible to penicillin. 
The increase of resistance to macrolides becomes a relevant problem. In the 1990s, ERY-R increased in Belgium from 3 to 
10% and the increase is still ongoing. In 2005-2006, with 32% of ERY-R, GBS isolated in Belgium are still quite susceptible by 
comparison to the 73% of resistance recently observed in France, a neighbor country.  
 High rates of resistance are particularly associated with serotypes IV, V, VI and VII.  
 In this study, by comparison to a Belgian previous surveillance (2001-2003), no more difference  was observed in the rate of 
ERY-R among isolates from either adults or neonates.  
 As previously reported in Belgium or in other European countries, most of ERY-R isolates had a MLS phenotype.  
 The detection of MLS-IR is important: the simple and reliable double-disk diffusion test is strongly recommended.
 Owing to this increasing prevalence of MLS resistance in GBS, neither macrolides no lincosamides should no longer be used 
without susceptibility testing.
GBS strains containing the ermB gene resulted in a variety of phenotypes as 
well as for isolates containing the ermTR genes.  The mechanisms of the 
phenotypic variation or expression of these genes were not investigated.
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